Firm said clinical trials for its Dexan (dextromethorphan) in irritable bowel syndrome may be completed by end of this year. "Preliminary results are very promising," firm's president, Eric Nelson, said at an Alex Brown seminar. Nelson predicted the first products incorporating its Azone controlled-release system should reach market in 1985.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.